Ellington Management Group’s Ionis Pharmaceuticals IONS Stock Holding History

Ellington Management Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,500	Closed	-$211K	–	647
2019 Q4	$211K	Sell	3,500 -9,300	-73%	-$554K	0.04%	435
2019 Q3	$767K	Buy	+12,800	New	+$834K	0.14%	158
2019 Q2	–	Sell	-9,100	Closed	-$739K	–	676
2019 Q1	$739K	Buy	9,100 +3,600	+65%	+$232K	0.13%	172
2018 Q4	$297K	Buy	+5,500	New	+$281K	0.09%	227
2017 Q3	–	Sell	-6,800	Closed	-$346K	–	733
2017 Q2	$346K	Buy	+6,800	New	+$317K	0.05%	354
2016 Q4	–	Sell	-5,900	Closed	-$216K	–	665
2016 Q3	$216K	Buy	+5,900	New	+$185K	0.06%	514
2015 Q4	–	Sell	-9,700	Closed	-$392K	–	686
2015 Q3	$392K	Buy	+9,700	New	+$502K	0.11%	316
2015 Q2	–	Sell	-11,600	Closed	-$739K	–	769
2015 Q1	$739K	Buy	+11,600	New	+$787K	0.15%	174

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ellington Management Group's IONS Position: Q1 2020 in Review

Ellington Management Group sold out of Ionis Pharmaceuticals (IONS) in Q1 2020, closing a stake of 3,500 shares — an estimated $211K sold.

Ellington Management Group first reported a position in IONS in Q1 2015 and held it in 8 quarters. The position peaked at $767K in Q3 2019. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2020.

Ellington Management Group reported no remaining Ionis Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Ellington Management Group sold 3,500 Ionis Pharmaceuticals shares in Q1 2020, an estimated $211K.
Ellington Management Group first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Ellington Management Group's Ionis Pharmaceuticals position peaked at $767K in Q3 2019.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.